Press Release July 28, 2022

Kelun-Biotech Announces Oncology Research Collaboration and License Agreement with MSD

The Life Sciences team advised Sichuan Kelun-Biotech Biopharmaceutical in its collaboration and exclusive license agreement with Merck Sharp & Dohme (MSD) to develop an investigational antibody drug conjugate (ADC) for the treatment of solid tumors.

Kelun Biotech is a clinical-stage biotech company established in 2016, a controlled subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd, engaged in biologic therapeutics as well as small molecule discovery and development. Sichuan Kelun Pharmaceutical Co., Ltd. is listed on Shenzhen Stock Exchange.

MSD is a global healthcare company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products.

Under the terms of the agreement, Kelun-Biotech has granted MSD global, exclusive rights to develop, manufacture and commercialize an investigational ADC. Kelun-Biotech and MSD will also collaborate on the early clinical development of the investigational ADC. In return, Kelun-Biotech will receive an upfront payment of $35 million and is eligible to receive future development, approval and commercial milestone payments totaling up to $901 million, plus tiered royalties on net sales.

The Goodwin team was led by Wenseng “Wendy” Pan, and supported by Kevin Guan, Paul Jin, Katie Kissinger and Michael Casaburi.

For more details, read the press release.